🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daniel B. Costa

Beth Israel Deaconess Medical Center

ORCID: 0000-0002-0689-395X

Also affiliated with Harvard University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.866Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Papers

Driven by 29 papers — median percentile 51. Top paper: “Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?”.

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000697
N/A
2.6DataRank · unranked
50 citations

Andreas Varkaris, Hollis Viray, Paul A. VanderLaan, Deepa Rangachari, Daniel B. Costa +1 more

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507
N/A
1.5DataRank · unranked
39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Frontiers in Oncology(2020)10.3389/fonc.2020.01193
N/A
0.470DataRank · unranked
22 citations

Daniel B. Costa, Deepa Rangachari, Kartik Sehgal

TIP60 is required for tumorigenesis in non‐small cell lung cancer

Cancer Science(2023)10.1111/cas.15785
N/A
0.449DataRank · unranked
19 citations

Naoki Akanuma, Ikei S. Kobayashi, Eunyoung Heo, Mariko Ando, Masanori Fujii +10 more

Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19

Cancer Medicine(2021)10.1002/cam4.3708
N/A
0.345DataRank · unranked
9 citations

Andrew J. Piper‐Vallillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin Patel, Daniel B. Costa +2 more

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung Cancer(2023)10.1016/j.lungcan.2023.107423
Top 72%
0.109DataRank
Top 72%1 citations

Chih–Yuan Hsu, Jennifer G. Whisenant, Melina E. Marmarelis, Carolyn J. Presley, Karen L. Reckamp +24 more

Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21579
N/A
0DataRank · unranked
0 citations

Ritu R. Gill, Poorva Bindal, Anita G. Koshy, Danielle C. McDonald, Deepa Rangachari +2 more

Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

UNC Libraries(2020)10.17615/v11w-c913
N/A
0DataRank · unranked
0 citations

Daniel G. Tenen, Richard H. Feins, Balázs Halmos, Daniel B. Costa, Sigui Li +4 more

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37120
N/A
0DataRank · unranked
165 citations

Ritu R. Gill, Page Widick, Poorva Bindal, Danielle C. McDonald, Meghan Shea +3 more

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2020.100133
N/A
0DataRank · unranked
0 citations

Susumu Kobayashi, Daniel B. Costa, Andrew J. Piper‐Vallillo

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Translational Lung Cancer Research(2023)10.21037/tlcr-23-98
N/A
0DataRank · unranked
33 citations

Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu Kobayashi, Paul A. VanderLaan +2 more

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100614
N/A
0DataRank · unranked
11 citations

William O. Shaffer, Hollis Viray, Deepa Rangachari, Paul A. VanderLaan, Susumu Kobayashi +2 more

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

Lung Cancer(2023)10.1016/j.lungcan.2023.107250
N/A
0DataRank · unranked
6 citations

Ikei S. Kobayashi, Daniel Sentana‐Lledo, Shriram K. Sundararaman, Meghan Lee, Deepa Rangachari +4 more

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100489
N/A
0DataRank · unranked
0 citations

Emmeline C. Academia, Soravis A. Osataphan, Deepa Rangachari, Sheida Sharifi, Paul A. VanderLaan +2 more

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

Targeted Oncology(2023)10.1007/s11523-023-01020-1
N/A
0DataRank · unranked
0 citations

Eric Nadler, Daniel B. Costa, John V. Heymach, Xiuning Le

Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer

Cell Death and Disease(2024)10.1038/s41419-024-06940-y
N/A
0DataRank · unranked
18 citations

Masanori Fujii, Ikei S. Kobayashi, Vivian Ho, Yukie Kashima, Hibiki Udagawa +3 more

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer

Lung Cancer(2024)10.1016/j.lungcan.2024.107885
N/A
0DataRank · unranked
15 citations

Daniel B. Costa, Susumu Kobayashi, Motohiro Izumi

Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology‐proven malignant pleural effusions

Cancer Cytopathology(2024)10.1002/cncy.22900
N/A
0DataRank · unranked
2 citations

Adnan Majid, Daniel B. Costa, Paul A. VanderLaan, Cristiana M. Pineda

A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas

Modern Pathology(2025)10.1016/j.modpat.2025.100938
N/A
0DataRank · unranked
1 citations

Zoe Guan, Hyunwoo Kwon, Deepa Rangachari, Daniel B. Costa, Paul A. VanderLaan +1 more

How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s

Translational Cancer Research(2025)10.21037/tcr-24-1827
N/A
0DataRank · unranked
1 citations

Toshiki A. Kobayashi, Daniel B. Costa, Julia M. Berg

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100051
N/A
0DataRank · unranked
81 citations

Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari +5 more

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Lung Cancer(2025)10.1016/j.lungcan.2025.108479
N/A
0DataRank · unranked
0 citations

Hiroki Izumi, Ikei S. Kobayashi, Shingo Matsumoto, Yukio Hosomi, Takae Okuno +23 more

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.05.028
N/A
0DataRank · unranked
22 citations

Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri +10 more

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100071
N/A
0DataRank · unranked
22 citations

Brian Halbert, Deepa Rangachari, Susumu Kobayashi, Daniel B. Costa, Andrew J. Piper‐Vallillo

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100105
N/A
0DataRank · unranked
23 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.28.317560
N/A
0DataRank · unranked
20 citations

Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa, Pedro Eduardo Nascimento Silva Vasconcelos

Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19

medRxiv(2020)10.1101/2020.07.23.20161000
N/A
0DataRank · unranked
6 citations

Andrew J. Piper-Valillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin Patel, Daniel B. Costa +2 more

Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9533
N/A
0DataRank · unranked
2 citations

Poorva Bindal, Anita G. Koshy, Ritu Gill, Danielle C. McDonald, Deepa Rangachari +2 more